Groisberg et al. found that 93 out of 102 advanced STS patients had at least one genetic alteration, where the most frequent were found in TP53, CDK4, and MDM2, and 61% had a potentially targetable alteration. This evidence concerns the gene TP53 and telomere syndrome.